Astrazeneca (AZN) Long-Term Debt Repayments (2016 - 2025)
Historic Long-Term Debt Repayments for Astrazeneca (AZN) over the last 8 years, with Q4 2025 value amounting to -$2.0 billion.
- Astrazeneca's Long-Term Debt Repayments fell 4008000.0% to -$2.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.0 billion, marking a year-over-year increase of 5638.44%. This contributed to the annual value of -$2.0 billion for FY2025, which is 5638.44% up from last year.
- According to the latest figures from Q4 2025, Astrazeneca's Long-Term Debt Repayments is -$2.0 billion, which was down 4008000.0% from -$4.0 million recorded in Q3 2025.
- In the past 5 years, Astrazeneca's Long-Term Debt Repayments ranged from a high of -$4.0 million in Q1 2022 and a low of -$2.6 billion during Q2 2024
- In the last 4 years, Astrazeneca's Long-Term Debt Repayments had a median value of -$632.5 million in 2022 and averaged -$945.5 million.
- In the last 5 years, Astrazeneca's Long-Term Debt Repayments crashed by 5000000.0% in 2023 and then surged by 9980.04% in 2025.
- Quarter analysis of 4 years shows Astrazeneca's Long-Term Debt Repayments stood at -$1.3 billion in 2022, then decreased by 12.05% to -$1.4 billion in 2023, then soared by 99.64% to -$5.0 million in 2024, then crashed by 40080.0% to -$2.0 billion in 2025.
- Its Long-Term Debt Repayments was -$2.0 billion in Q4 2025, compared to -$4.0 million in Q3 2025 and -$12.0 million in Q2 2025.